A Phase 1/2 interventional study of Forimtamig and Carfilzomib in Relapsed or Refractory Multiple Myeloma, sponsored by Hoffmann-La Roche. Terminated at 8 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-29.
Sponsored by Hoffmann-La Roche · Phase 1/2, Interventional, and Treatment
The study was terminated prematurely because the Sponsor decided not to pursue the development of forimtamig.
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 30 studies in Multiple Myeloma by Hoffmann-La Roche — 6 open to participants now, 12 under way, 1 of them phase 3. Multiple Myeloma · Hoffmann-La Roche.
Among the 30 studies in Multiple Myeloma by Hoffmann-La Roche, this one is the 24th largest by enrollment of the 29 interventional ones that give a count, is one of 4 that started in 2023, is one of 5 in phase 1/2, and was the 25th registered.
3,764 studies on the registry are indexed under Multiple Myeloma; 768 are open to participants now.
Browse Multiple Myeloma studies →6 of the 30 studies in Multiple Myeloma by Hoffmann-La Roche are open now, in 12 countries. Recruiting first, the newest first:
Hoffmann-La Roche · Sites in Germany
Ages 18+
Hoffmann-La Roche · Sites in United States, Australia, Brazil and 15 more countries
Ages 18+
Genentech, Inc. · Sites in Australia, Korea, Republic of
Ages 18+
Hoffmann-La Roche · Sites in Australia, France, Germany and 3 more countries
Ages 18+
Genentech, Inc. · Sites in Australia, Israel, Korea, Republic of
Ages 18+
By country, each count listing its studies:
Of the 583 Multiple Myeloma studies recruiting now, 428 (73%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
30 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 23 · Phase 2 9 · Phase 3 2
First in 2006; this study’s year is marked. 4 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 21 is below the median of 41 across 3,009 interventional studies indexed under Multiple Myeloma.
Median enrollment 90 across the 29 interventional studies, 662 across the 1 observational. Of the 18 that completed or were terminated, 9 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 88 are open to participants now.
Of its 331 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
2 of the studies in Multiple Myeloma by Hoffmann-La Roche that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05535244Hoffmann-La RocheA Study Evaluating the Efficacy and Safety of Cevostamab in Prior B Cell Maturation Antigen (BCMA)-Exposed Participants With Relapsed/Refractory Multiple Myeloma | 2027-02-26 |
| NCT05927571Genentech, Inc.A Study Evaluating the Safety, Pharmacokinetics, and Activity of the Combination of Cevostamab and Elranatamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM) | 2027-07-31 |
Add all 2 to your calendar (.ics) → With an account.
Among the 30 studies in Multiple Myeloma by Hoffmann-La Roche, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the safety, tolerability, and preliminary anti-tumor activity of forimtamig when administered alone or in combination with carfilzomib or daratumumab or other combination partners in participants with relapsed or refractory multiple myeloma (r/r MM). The study consists of two phases: a dose exploration phase and a dose-expansion phase.
3,764 studies on the registry are indexed under Multiple Myeloma; 768 are open to participants now.
This study's enrollment of 21 is below the median of 41 across 3,009 interventional studies indexed under Multiple Myeloma.
Browse Multiple Myeloma studies →Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 88 are open to participants now.
Of its 331 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
Compared within Multiple Myeloma, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Recurrence. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive Dose 1 of forimtamig, subcutaneous (SC) injection in combination with carfilzomib, intravenous (IV) infusion until disease progression.
Drug: Forimtamig · Drug: Carfilzomib
Participants will receive Dose 2 of forimtamig, SC injection in combination with carfilzomib, IV infusion until disease progression.
Drug: Forimtamig · Drug: Carfilzomib
Participants will receive Dose 3 of forimtamig, SC injection in combination with carfilzomib, IV infusion until disease progression.
Drug: Forimtamig · Drug: Carfilzomib
Participants will receive Dose 1 of forimtamig, SC injection in combination with daratumumab, SC injection until disease progression.
Drug: Forimtamig · Drug: Daratumumab
Participants will receive Dose 2 of forimtamig, SC injection in combination with daratumumab, SC injection until disease progression.
Drug: Forimtamig · Drug: Daratumumab
Participants will receive Dose 3 of forimtamig, SC injection in combination with daratumumab, SC injection until disease progression.
Drug: Forimtamig · Drug: Daratumumab
Participants will receive forimtamig, SC injection at a fixed dose determined during dose exploration phase until disease progression or completion of 12 months of treatment, whichever occurs first.
Drug: Forimtamig
Participants will receive forimtamig, SC injection at a fixed dose determined during dose exploration phase in combination with carfilzomib, IV infusion until disease progression.
Drug: Forimtamig · Drug: Carfilzomib
Participants will receive forimtamig, SC injection at a fixed dose determined during dose exploration phase in combination with daratumumab, SC injection until disease progression.
Drug: Forimtamig · Drug: Daratumumab
Forimtamig will be administered SC at different doses during dose exploration phase. Forimtamig will be administered at a fixed dose determined during dose exploration phase in dose expansion phase.
Carfilzomib will be administered via IV infusion in combination with forimtamig.
Daratumumab will be administered via SC injection in combination with forimtamig.
Number of Participants With Adverse Effects (AEs)
AE was defined as any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product, regardless of causal attribution. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.
Time frame: From initiation of study treatment up to approximately 15.7 months
Number of Participants With Cytokine Release Syndrome (CRS), With Severity Determined According to American Society of Transplantation and Cellular Therapy (ASTCT) Consensus Grading
CRS=supraphysiologic response following administration of any immune therapy that results in activation/engagement of endogenous or infused T cells and/or other immune effector cells. Symptoms may be progressive, including fever at onset, headache, and myalgia and may also include hypotension, capillary leak (hypoxia), dyspnea, chest discomfort and end-organ dysfunction. Severity of CRS was determined per ASTCT Consensus Grading Criteria, which categorizes CRS into 5 grades- Grade 1: Fever (≥38◦Celsius), with/without constitutional symptoms, in absence of hypotension \& hypoxia; Grade 2: Fever with hypotension not requiring vasopressors and/or hypoxia requiring low-flow oxygen; Grade 3: Fever with hypotension requiring one vasopressor, with/without vasopressin, and/or hypoxia requiring high-flow oxygen; Grade 4: Fever accompanied by hypotension requiring multiple vasopressors (excluding vasopressin) and/or hypoxia requiring positive-pressure ventilation; Grade 5: death due to CRS.
Time frame: From initiation of study treatment up to approximately 15.7 months
Number of Participants With Immune Effector Cell-associated Neurotoxicity Syndrome (ICANS), With Severity Determined According to ASTCT Consensus Grading
ICANS grade is determined by the most severe event (immune effector cell-associated encephalopathy \[ICE\] score, level of consciousness, seizures, motor findings, raised intracranial pressure \[ICP\]/cerebral edema) not attributed to any other cause. Grade 1=ICE score of 7-9; awakens spontaneously; no seizure/motor findings/elevated ICP/cerebral edema. Grade 2=ICE score of 3-6; awakes voice; no seizure/motor findings/elevated ICP/cerebral edema. Grade 3=ICE score of 0-2; awakes only to tactile stimulus; any clinical seizure focal or generalized that resolves rapidly or nonconvulsive seizure on EEG that resolves with intervention; no motor findings; focal/local edema on neuroimaging.
Time frame: From initiation of study treatment up to approximately 15.7 months
Investigator-assessed Objective Response Rate (ORR) Per International Myeloma Working Group (IMWG) Response Criteria
ORR=percentage of participants with stringent complete response (sCR), complete response (CR), very good partial response (VGPR), or partial response (PR) per IMWG response criteria. CR \& sCR are defined as outlined in endpoint 5 (CRR/sCRR). VGPR=serum \& urine M-protein (UMP) detectable by immunofixation, but not electrophoresis; ≥90% reduction in serum M-protein (SMP) + UMP level \<100 mg/24 hrs; at baseline ≥90% reduction in sum of the maximal perpendicular diameter (SPD) compared with baseline for soft tissue plasmacytoma \& ≥90% decrease in the difference between involved \& uninvolved SFLC levels. PR=≥50% reduction in SMP \& UMP reduction ≥90% or \<200 mg/24hours; if SMP \& UMP not measurable, ≥50% decrease in involved \& uninvolved SFLC difference in place of M-protein criteria; if SMP, UMP \& SFLC assay not unmeasurable, ≥50% reduction in plasma cells required in place of M-protein (baseline BM plasma cell ≥30%); at baseline, a ≥50% reduction in SPD of soft tissue plasmacytomas.
Time frame: Up to approximately 15.2 months
Investigator-assessed Complete Response Rate (CRR) / Stringent Complete Response Rate (sCRR) Per IMWG Response Criteria
CRR and sCRR were defined as the percentage of participants with CR or sCR, as determined by the investigator per IMWG response criteria. CR was defined as: no evidence of initial monoclonal protein isotype(s) on immunofixation of the serum \& urine; Disappearance of any soft tissue plasmacytomas; \<5% plasma cells in BM \& a normal SFLC ratio of 0.26-1.65. sCR was defined as: CR (defined above); normal SFLC ratio, \& absence of clonal cells in BM by IHC or negative by 2-4 color flow cytometry. CR and sCR are distinct response categories and are evaluated and reported separately in accordance with the defined response criteria i.e., if a response is clinically upgraded from CR to sCR it is not further considered a CR but solely a sCR. Percentages have been rounded off.
Time frame: Up to approximately 15.2 months
Investigator-assessed VGPR Rate or Better Per IMWG Response Criteria
VGPR rate was defined as the percentage of participants with VGPR as determined by the investigator per IMWG response criteria. VGPR was defined as: serum \& UMP detectable by immunofixation, but not on electrophoresis; or ≥90% reduction in SMP plus UMP level \<100 mg/24 hours; at baseline ≥90% reduction in SPD compared with baseline for soft tissue plasmacytoma \& ≥90% decrease in the difference between involved \& uninvolved SFLC levels. Responses better than VGPR include CR and sCR (as defined in endpoint 5). Percentages have been rounded off.
Time frame: Up to approximately 15.2 months
Investigator-assessed Progression-free Survival (PFS) Per IMWG Response Criteria
PFS=time from randomization until disease progression (PD) per IMWG criteria or death from any cause. PD=any 1 or more of the following: Increase of 25% from lowest response value in any of the following: Serum M-component, Urine M-component or in participants without measurable SMP \& UMP levels: difference between involved \& uninvolved FLC levels; For non-secretory participants at study entry: in participants without measurable SMP \& UMP levels \& without measurable disease by FLC: BM plasma cell percentage irrespective of baseline status (absolute %must be ≥10%); appearance of a new lesion/s, ≥ 50% increase from nadir in SPD of \>1 lesion, or ≥50% increase in the longest diameter of a previous lesion \>1centimeters (cm) in short axis; Definite development of new bone lesions/definite increase in the size of existing bone lesions; ≥50% increase in circulating plasma cells. Kaplan-Meier (K-M) method was used to estimate the median PFS. Overall number analyzed=participants with an event.
Time frame: Up to approximately 15.2 months
Investigator-assessed Duration of Response (DoR) for Participants Who Achieved PR or Better
DoR was defined as the time from the initial objective response (OR) (sCR, CR, PR, or VGPR) to the time of PD or death from any cause as determined by the investigator per IMWG response criteria. CR, sCR, VGPR, and PR were defined the same as outlined in the description for the primary endpoint ORR. PD was defined as outlined in the description for the endpoint PFS. K-M method was used to estimate the median DOR.
Time frame: Up to approximately 15.2 months
Investigator-assessed Time to Response (TTR) Per IMWG Response Criteria
TTR was defined as the time from randomization until an OR (PR or better), as determined by the investigator per IMWG response criteria. CR, sCR, VGPR and PR were defined the same as outlined in the description for the primary endpoint ORR. K-M method was used to estimate the median TTR.
Time frame: Up to approximately 15.2 months
Investigator-assessed Time to Best Response (TTBR) Per IMWG Response Criteria
TTBR was defined as the time from randomization until the best OR (sCR, CR, VGPR, or PR), as determined by the investigator per IMWG response criteria. CR, sCR, VGPR and PR were defined the same as outlined in the description for the primary endpoint ORR. K-M method was used to estimate the median TTBR.
Time frame: Up to approximately 15.2 months
Investigator-assessed Overall Survival (OS)
OS was defined as the time from randomization to death from any cause as determined by the investigator per IMWG response criteria. Participants who were still alive at the time of OS analysis were censored at the last date they were known to be alive. K-M method was used to estimate the median OS.
Time frame: Up to approximately 15.7 months
Number of Participants With Anti-drug Antibodies (ADAs) to Forimtamig
Participants who received forimtamig were considered to be treatment-emergent ADA-positive if they were ADA-negative or had missing data at baseline but developed an ADA response following forimtamig exposure (treatment-induced ADA response), or if they were ADA-positive at baseline and the titer of one or more post-baseline samples was at least 0.60 titer units (t.u.) greater than the titer of the baseline sample (treatment-enhanced ADA response). Participants with a positive post-baseline sample have been reported here.
Time frame: Up to approximately 15.7 months
Serum Concentrations of Forimtamig at the Specified Timepoints
Time frame: Pre-dose on Day (D)1 of Cycle (C)1,2&4, D4 of C1&5, D2C3; 4hours post-dose on D1,4 of C1, D2C3, D1C4, D4C5; D2,8,9,11,15,16&18 of C1; D2,8,15,22 of C2&4; D1,4,8,15,22 of C3; D1,8,15 of C5; D1,4,8,15 of C6,7,8&9; D1,4,8 of C10
Area Under the Concentration-time Curve From Dosing to the Time of the Last Measured Concentration (AUClast) of Forimtamig
Time frame: Up to Day 15 of Cycle 3 (1 cycle=28 days)
Maximum Observed Concentration (Cmax) of Forimtamig
Time frame: Day 1 of Cycle 3 (1 cycle=28 days)
A total of 21 participants with relapsing or refractory multiple myeloma (r/r MM) took part in the study at 9 investigative sites across Korea, Australia, Italy, New Zealand, Canada, and Spain from 08 December 2023 to 08 July 2025.
| Milestone | Cohort 1: Arm B1: Forimtamig 0.3 mg + Carfilzomib | Cohort 1: Arm B2: Forimtamig 0.75 mg + Carfilzomib | Cohort 1: Arm B3: Forimtamig 1.5 mg + Carfilzomib |
|---|---|---|---|
| Started | 7 | 7 | 7 |
| Safety population | 7 | 6 | 6 |
| Completed | 2 | 1 | 0 |
| Not completed | 5 | 6 | 7 |
| Withdrew: Death | 0 | 1 | 1 |
| Withdrew: Study terminated by sponsor | 3 | 3 | 4 |
| Withdrew: Withdrawal by subject | 2 | 1 | 1 |
| Withdrew: Did not start study treatment | 0 | 1 | 1 |
AE was defined as any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product, regardless of causal attribution. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.
| Participants | Cohort 1: Arm B1: Forimtamig 0.3 mg + Carfilzomib | Cohort 1: Arm B2: Forimtamig 0.75 mg + Carfilzomib | Cohort 1: Arm B3: Forimtamig 1.5 mg + Carfilzomib |
|---|---|---|---|
| Number of Participants With Adverse Effects (AEs) | 7 | 6 | 6 |
CRS=supraphysiologic response following administration of any immune therapy that results in activation/engagement of endogenous or infused T cells and/or other immune effector cells. Symptoms may be progressive, including fever at onset, headache, and myalgia and may also include hypotension, capillary leak (hypoxia), dyspnea, chest discomfort and end-organ dysfunction. Severity of CRS was determined per ASTCT Consensus Grading Criteria, which categorizes CRS into 5 grades- Grade 1: Fever (≥38◦Celsius), with/without constitutional symptoms, in absence of hypotension \& hypoxia; Grade 2: Fever with hypotension not requiring vasopressors and/or hypoxia requiring low-flow oxygen; Grade 3: Fever with hypotension requiring one vasopressor, with/without vasopressin, and/or hypoxia requiring high-flow oxygen; Grade 4: Fever accompanied by hypotension requiring multiple vasopressors (excluding vasopressin) and/or hypoxia requiring positive-pressure ventilation; Grade 5: death due to CRS.
| Participants | Cohort 1: Arm B1: Forimtamig 0.3 mg + Carfilzomib | Cohort 1: Arm B2: Forimtamig 0.75 mg + Carfilzomib | Cohort 1: Arm B3: Forimtamig 1.5 mg + Carfilzomib |
|---|---|---|---|
| Step-up Dose 1 - Grade 1 | 1 | 1 | 2 |
| Step-up Dose 1 - Grade 2 | 0 | 1 | 0 |
| Step-up Dose 1 - Grade 3 | 0 | 0 | 1 |
| Step-up Dose 2 - Grade 1 | 3 | 4 | 4 |
| Target Dose 1 - Grade 1 | 0 | 2 | 3 |
| Target Dose 1 - Grade 2 | 1 | 0 | 0 |
| Cycle 2 - Grade 1 | 2 | 1 | 1 |
| Cycle 3+ - Grade 1 | 2 | 1 | 1 |
ICANS grade is determined by the most severe event (immune effector cell-associated encephalopathy \[ICE\] score, level of consciousness, seizures, motor findings, raised intracranial pressure \[ICP\]/cerebral edema) not attributed to any other cause. Grade 1=ICE score of 7-9; awakens spontaneously; no seizure/motor findings/elevated ICP/cerebral edema. Grade 2=ICE score of 3-6; awakes voice; no seizure/motor findings/elevated ICP/cerebral edema. Grade 3=ICE score of 0-2; awakes only to tactile stimulus; any clinical seizure focal or generalized that resolves rapidly or nonconvulsive seizure on EEG that resolves with intervention; no motor findings; focal/local edema on neuroimaging.
| Participants | Cohort 1: Arm B1: Forimtamig 0.3 mg + Carfilzomib | Cohort 1: Arm B2: Forimtamig 0.75 mg + Carfilzomib | Cohort 1: Arm B3: Forimtamig 1.5 mg + Carfilzomib |
|---|---|---|---|
| Grade 1 | 3 | 1 | 2 |
| Grade 2 | 0 | 1 | 1 |
| Grade 3 | 1 | 0 | 0 |
ORR=percentage of participants with stringent complete response (sCR), complete response (CR), very good partial response (VGPR), or partial response (PR) per IMWG response criteria. CR \& sCR are defined as outlined in endpoint 5 (CRR/sCRR). VGPR=serum \& urine M-protein (UMP) detectable by immunofixation, but not electrophoresis; ≥90% reduction in serum M-protein (SMP) + UMP level \<100 mg/24 hrs; at baseline ≥90% reduction in sum of the maximal perpendicular diameter (SPD) compared with baseline for soft tissue plasmacytoma \& ≥90% decrease in the difference between involved \& uninvolved SFLC levels. PR=≥50% reduction in SMP \& UMP reduction ≥90% or \<200 mg/24hours; if SMP \& UMP not measurable, ≥50% decrease in involved \& uninvolved SFLC difference in place of M-protein criteria; if SMP, UMP \& SFLC assay not unmeasurable, ≥50% reduction in plasma cells required in place of M-protein (baseline BM plasma cell ≥30%); at baseline, a ≥50% reduction in SPD of soft tissue plasmacytomas.
| percentage of participants | Cohort 1: Arm B1: Forimtamig 0.3 mg + Carfilzomib | Cohort 1: Arm B2: Forimtamig 0.75 mg + Carfilzomib | Cohort 1: Arm B3: Forimtamig 1.5 mg + Carfilzomib |
|---|---|---|---|
| Investigator-assessed Objective Response Rate (ORR) Per International Myeloma Working Group (IMWG) Response Criteria | 85.7 (42.13 to 99.64) | 83.3 (35.88 to 99.58) | 83.3 (35.88 to 99.58) |
CRR and sCRR were defined as the percentage of participants with CR or sCR, as determined by the investigator per IMWG response criteria. CR was defined as: no evidence of initial monoclonal protein isotype(s) on immunofixation of the serum \& urine; Disappearance of any soft tissue plasmacytomas; \<5% plasma cells in BM \& a normal SFLC ratio of 0.26-1.65. sCR was defined as: CR (defined above); normal SFLC ratio, \& absence of clonal cells in BM by IHC or negative by 2-4 color flow cytometry. CR and sCR are distinct response categories and are evaluated and reported separately in accordance with the defined response criteria i.e., if a response is clinically upgraded from CR to sCR it is not further considered a CR but solely a sCR. Percentages have been rounded off.
| percentage of participants | Cohort 1: Arm B1: Forimtamig 0.3 mg + Carfilzomib | Cohort 1: Arm B2: Forimtamig 0.75 mg + Carfilzomib | Cohort 1: Arm B3: Forimtamig 1.5 mg + Carfilzomib |
|---|---|---|---|
| sCR | 28.6 (3.67 to 70.96) | 33.3 (4.33 to 77.72) | 33.3 (4.33 to 77.72) |
| CR | 28.6 (3.67 to 70.96) | 16.7 (0.42 to 64.12) | 0 (0.00 to 45.93) |
VGPR rate was defined as the percentage of participants with VGPR as determined by the investigator per IMWG response criteria. VGPR was defined as: serum \& UMP detectable by immunofixation, but not on electrophoresis; or ≥90% reduction in SMP plus UMP level \<100 mg/24 hours; at baseline ≥90% reduction in SPD compared with baseline for soft tissue plasmacytoma \& ≥90% decrease in the difference between involved \& uninvolved SFLC levels. Responses better than VGPR include CR and sCR (as defined in endpoint 5). Percentages have been rounded off.
| percentage of participants | Cohort 1: Arm B1: Forimtamig 0.3 mg + Carfilzomib | Cohort 1: Arm B2: Forimtamig 0.75 mg + Carfilzomib | Cohort 1: Arm B3: Forimtamig 1.5 mg + Carfilzomib |
|---|---|---|---|
| Investigator-assessed VGPR Rate or Better Per IMWG Response Criteria | 85.7 (42.13 to 99.64) | 83.3 (35.88 to 99.58) | 50.0 (11.81 to 88.19) |
PFS=time from randomization until disease progression (PD) per IMWG criteria or death from any cause. PD=any 1 or more of the following: Increase of 25% from lowest response value in any of the following: Serum M-component, Urine M-component or in participants without measurable SMP \& UMP levels: difference between involved \& uninvolved FLC levels; For non-secretory participants at study entry: in participants without measurable SMP \& UMP levels \& without measurable disease by FLC: BM plasma cell percentage irrespective of baseline status (absolute %must be ≥10%); appearance of a new lesion/s, ≥ 50% increase from nadir in SPD of \>1 lesion, or ≥50% increase in the longest diameter of a previous lesion \>1centimeters (cm) in short axis; Definite development of new bone lesions/definite increase in the size of existing bone lesions; ≥50% increase in circulating plasma cells. Kaplan-Meier (K-M) method was used to estimate the median PFS. Overall number analyzed=participants with an event.
| months | Cohort 1: Arm B1: Forimtamig 0.3 mg + Carfilzomib | Cohort 1: Arm B2: Forimtamig 0.75 mg + Carfilzomib | Cohort 1: Arm B3: Forimtamig 1.5 mg + Carfilzomib |
|---|---|---|---|
| Investigator-assessed Progression-free Survival (PFS) Per IMWG Response Criteria | NA (8.9 to NA) | NA (6.5 to NA) | 10.8 (5.6 to NA) |
DoR was defined as the time from the initial objective response (OR) (sCR, CR, PR, or VGPR) to the time of PD or death from any cause as determined by the investigator per IMWG response criteria. CR, sCR, VGPR, and PR were defined the same as outlined in the description for the primary endpoint ORR. PD was defined as outlined in the description for the endpoint PFS. K-M method was used to estimate the median DOR.
| months | Cohort 1: Arm B1: Forimtamig 0.3 mg + Carfilzomib | Cohort 1: Arm B2: Forimtamig 0.75 mg + Carfilzomib | Cohort 1: Arm B3: Forimtamig 1.5 mg + Carfilzomib |
|---|---|---|---|
| Investigator-assessed Duration of Response (DoR) for Participants Who Achieved PR or Better | NA (6.9 to NA) | NA (5.6 to NA) | 7.2 (4.6 to NA) |
TTR was defined as the time from randomization until an OR (PR or better), as determined by the investigator per IMWG response criteria. CR, sCR, VGPR and PR were defined the same as outlined in the description for the primary endpoint ORR. K-M method was used to estimate the median TTR.
| months | Cohort 1: Arm B1: Forimtamig 0.3 mg + Carfilzomib | Cohort 1: Arm B2: Forimtamig 0.75 mg + Carfilzomib | Cohort 1: Arm B3: Forimtamig 1.5 mg + Carfilzomib |
|---|---|---|---|
| Investigator-assessed Time to Response (TTR) Per IMWG Response Criteria | 2.0 (1.4 to 2.1) | 1.5 (1.0 to 1.9) | 1.4 (1.2 to NA) |
TTBR was defined as the time from randomization until the best OR (sCR, CR, VGPR, or PR), as determined by the investigator per IMWG response criteria. CR, sCR, VGPR and PR were defined the same as outlined in the description for the primary endpoint ORR. K-M method was used to estimate the median TTBR.
| months | Cohort 1: Arm B1: Forimtamig 0.3 mg + Carfilzomib | Cohort 1: Arm B2: Forimtamig 0.75 mg + Carfilzomib | Cohort 1: Arm B3: Forimtamig 1.5 mg + Carfilzomib |
|---|---|---|---|
| Investigator-assessed Time to Best Response (TTBR) Per IMWG Response Criteria | 4.8 (3.8 to 5.0) | 3.0 (1.2 to 7.8) | 2.9 (1.2 to 4.4) |
OS was defined as the time from randomization to death from any cause as determined by the investigator per IMWG response criteria. Participants who were still alive at the time of OS analysis were censored at the last date they were known to be alive. K-M method was used to estimate the median OS.
| months | Cohort 1: Arm B1: Forimtamig 0.3 mg + Carfilzomib | Cohort 1: Arm B2: Forimtamig 0.75 mg + Carfilzomib | Cohort 1: Arm B3: Forimtamig 1.5 mg + Carfilzomib |
|---|---|---|---|
| Investigator-assessed Overall Survival (OS) | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) |
Participants who received forimtamig were considered to be treatment-emergent ADA-positive if they were ADA-negative or had missing data at baseline but developed an ADA response following forimtamig exposure (treatment-induced ADA response), or if they were ADA-positive at baseline and the titer of one or more post-baseline samples was at least 0.60 titer units (t.u.) greater than the titer of the baseline sample (treatment-enhanced ADA response). Participants with a positive post-baseline sample have been reported here.
| Participants | Cohort 1: Arm B1: Forimtamig 0.3 mg + Carfilzomib | Cohort 1: Arm B2: Forimtamig 0.75 mg + Carfilzomib | Cohort 1: Arm B3: Forimtamig 1.5 mg + Carfilzomib |
|---|---|---|---|
| Number of Participants With Anti-drug Antibodies (ADAs) to Forimtamig | 1 | 2 | 0 |
| nanograms per milliliter (ng/mL) | Cohort 1: Arm B1: Forimtamig 0.3 mg + Carfilzomib | Cohort 1: Arm B2: Forimtamig 0.75 mg + Carfilzomib | Cohort 1: Arm B3: Forimtamig 1.5 mg + Carfilzomib |
|---|---|---|---|
| Pre-dose Cycle 1 Day 1 | NA ± NA | NA ± NA | NA ± NA |
| 4hours Post-dose Cycle 1 Day 1 | NA ± NA | NA ± NA | NA ± NA |
| Cycle 1 Day 2 | 6.21 ± 109.6 | 2.76 ± 94.8 | 2.44 ± 250.5 |
| Pre-dose Cycle 1 Day 4 | 6.55 ± 50.8 | 3.69 ± 115.3 | 2.64 ± 384.1 |
| 4 hours Post-dose Cycle 1 Day 4 | 7.26 ± 52.4 | 6.99 ± 69.9 | NA ± NA |
| Cycle 1 Day 8 | 10.3 ± 44.7 | 21.4 ± 51.6 | 25.4 ± 434.0 |
| Cycle 1 Day 9 | 13.0 ± 33.9 | 14.9 ± 589.1 | 39.3 ± 268.2 |
| Cycle 1 Day 11 | NA ± NA | NA ± NA | NA ± NA |
| Cycle 1 Day 15 | NA ± NA | NA ± NA | 0.367 ± 100.8 |
| Cycle 1 Day 16 | 17.0 ± 13.8 | 18.9 ± NA | 147 ± NA |
| Cycle 1 Day 18 | 23.2 ± 0.6 | 27.7 ± NA | 178 ± NA |
| Pre-dose Cycle 2 Day 1 | 0.712 ± 121.8 | NA ± NA | NA ± NA |
| 4hours Post-dose Cycle 2 Day 1 | 2.08 ± 98.1 | 0.363 ± 120.4 | NA ± NA |
| Cycle 2 Day 2 | 3.89 ± 157.2 | 1.36 ± 83.4 | 1.57 ± 321.8 |
| Cycle 2 Day 8 | 14.1 ± NA | 8.82 ± NA | — |
| Cycle 2 Day 15 | 23.8 ± NA | — | — |
| Cycle 2 Day 22 | 29.4 ± 34.5 | 38.6 ± NA | 212 ± NA |
| Cycle 3 Day 1 | 26.0 ± NA | 28.1 ± NA | — |
| Pre-dose Cycle 3 Day 2 | 10.6 ± 72.2 | 25.6 ± 74.1 | 11.8 ± 379.4 |
| 4hours Post-dose Cycle 3 Day 2 | 11.9 ± 61.2 | 27.9 ± 97.7 | 10.2 ± 344.1 |
| Cycle 3 Day 4 | 11.5 ± 61.3 | 20.0 ± 109.7 | 23.0 ± 319.2 |
| Cycle 3 Day 8 | 16.1 ± 88.8 | 35.0 ± 114.6 | 25.0 ± 293.4 |
| Cycle 3 Day 15 | 19.2 ± 48.3 | 67.4 ± 60.5 | 43.7 ± 378.9 |
| Cycle 3 Day 22 | 19.2 ± 69.4 | 54.2 ± 53.0 | 32.9 ± 446.0 |
| Pre-dose Cycle 4 Day 1 | 13.1 ± 29.6 | 28.4 ± 44.6 | 24.0 ± 401.5 |
| 4hours Post-dose Cycle 4 Day 1 | 14.8 ± 37.9 | 26.9 ± 56.9 | 44.3 ± 273.3 |
| Cycle 4 Day 2 | 17.4 ± 29.3 | 27.9 ± 152.3 | 42.9 ± 220.0 |
| Cycle 4 Day 8 | 20.1 ± 50.1 | 44.8 ± 61.5 | 124 ± 11.5 |
| Cycle 4 Day 15 | 27.8 ± 37.4 | 61.0 ± 66.1 | 97.9 ± 25.5 |
| Cycle 4 Day 22 | 25.6 ± 46.4 | 60.7 ± 83.6 | 175 ± 14.5 |
| Cycle 5 Day 1 | 25.5 ± 42.9 | 72.8 ± 9.5 | 87.0 ± 254.2 |
| Pre-dose Cycle 5 Day 4 | 19.8 ± 25.1 | 32.5 ± 61.2 | 39.2 ± 221.2 |
| 4hours Post-dose Cycle 5 Day 4 | 17.3 ± 15.5 | 29.7 ± 68.3 | 96.4 ± 18.8 |
| Cycle 5 Day 8 | 19.8 ± 28.4 | 36.3 ± 40.4 | 34.0 ± 492.5 |
| Cycle 5 Day 15 | 23.1 ± 25.8 | 38.9 ± 83.2 | 145 ± 4.9 |
| Cycle 6 Day 1 | 28.0 ± 34.5 | 41.3 ± 104.3 | 103 ± NA |
| Cycle 6 Day 4 | 26.4 ± 34.0 | 44.7 ± 69.9 | 66.3 ± 404.6 |
| Cycle 6 Day 8 | 19.0 ± 31.6 | NA ± NA | 41.7 ± 113.7 |
| Cycle 6 Day 15 | 18.0 ± 58.8 | 20.2 ± 262.3 | 62.1 ± 133.8 |
| Cycle 7 Day 1 | 27.6 ± 57.8 | 10.3 ± 143751.7 | 140 ± NA |
| Cycle 7 Day 4 | 23.9 ± 67.1 | 73.5 ± 19.5 | 88.7 ± 104.1 |
| Cycle 7 Day 8 | 12.4 ± 58.4 | 24.4 ± 158.9 | 76.4 ± 50.3 |
| Cycle 7 Day 15 | 6.52 ± 265.7 | 24.9 ± NA | 98.2 ± 52.4 |
| Cycle 8 Day 1 | 20.0 ± 25.8 | 52.8 ± 74.3 | 171 ± NA |
| Cycle 8 Day 4 | 20.2 ± 13.0 | 53.6 ± 47.4 | 91.7 ± 60.4 |
| Cycle 8 Day 8 | 12.1 ± 78.4 | 21.3 ± 24.8 | 78.6 ± 45.8 |
| Cycle 8 Day 15 | 16.4 ± 3.5 | 21.6 ± 148.2 | 153 ± NA |
| Cycle 9 Day 1 | 24.0 ± 52.1 | 71.0 ± NA | 136 ± 19.9 |
| Cycle 9 Day 4 | 22.9 ± 33.1 | 65.4 ± NA | 109 ± 23.4 |
| Cycle 9 Day 8 | — | 32.3 ± NA | 121 ± NA |
| Cycle 9 Day 15 | 31.6 ± 17.8 | 45.7 ± NA | 195 ± NA |
| Cycle 10 Day 1 | 19.4 ± 4.7 | 10.8 ± NA | 146 ± NA |
| Cycle 10 Day 4 | 9.30 ± NA | 17.8 ± NA | — |
| Cycle 10 Day 8 | 41.4 ± NA | 30.8 ± NA | 135 ± NA |
| nanograms*hour/milliliter (ng*hr/mL) | Cohort 1: Arm B1: Forimtamig 0.3 mg + Carfilzomib | Cohort 1: Arm B2: Forimtamig 0.75 mg + Carfilzomib | Cohort 1: Arm B3: Forimtamig 1.5 mg + Carfilzomib |
|---|---|---|---|
| Area Under the Concentration-time Curve From Dosing to the Time of the Last Measured Concentration (AUClast) of Forimtamig | 9060 ± 34.5 | 13600 ± 92.9 | 29500 ± 348 |
| ng/mL | Cohort 1: Arm B1: Forimtamig 0.3 mg + Carfilzomib | Cohort 1: Arm B2: Forimtamig 0.75 mg + Carfilzomib | Cohort 1: Arm B3: Forimtamig 1.5 mg + Carfilzomib |
|---|---|---|---|
| Maximum Observed Concentration (Cmax) of Forimtamig | 31.7 ± 51.2 | 57.7 ± 95.0 | 89.6 ± 263 |
Collected over From initiation of study treatment up to approximately 15.7 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cohort 1: Arm B1: Forimtamig 0.3 mg + Carfilzomib | 0/7 (0%) | 5/7 (71.4%) | 7/7 (100%) |
| Cohort 1: Arm B2: Forimtamig 0.75 mg + Carfilzomib | 1/6 (16.7%) | 3/6 (50%) | 6/6 (100%) |
| Cohort 1: Arm B3: Forimtamig 1.5 mg + Carfilzomib | 1/6 (16.7%) | 4/6 (66.7%) | 6/6 (100%) |
| Event | Cohort 1: Arm B1: Forimtamig 0.3 mg + Carfilzomib | Cohort 1: Arm B2: Forimtamig 0.75 mg + Carfilzomib | Cohort 1: Arm B3: Forimtamig 1.5 mg + Carfilzomib |
|---|---|---|---|
| Cytokine release syndromeImmune system disorders | 1/7 | 2/6 | 3/6 |
| PyrexiaGeneral disorders | 2/7 | 1/6 | 2/6 |
| PneumoniaInfections and infestations | 0/7 | 0/6 | 1/6 |
| SepsisInfections and infestations | 1/7 | 0/6 | 1/6 |
| Bone painMusculoskeletal and connective tissue disorders | 0/7 | 1/6 | 0/6 |
| Cauda equina syndromeNervous system disorders | 0/7 | 1/6 | 0/6 |
| Pleural effusionRespiratory, thoracic and mediastinal disorders | 0/7 | 0/6 | 1/6 |
| Deep vein thrombosisVascular disorders | 0/7 | 1/6 | 0/6 |
| Anaphylactic reactionImmune system disorders | 1/7 | 0/6 | 0/6 |
| Squamous cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/7 | 0/6 | 0/6 |
| Event | Cohort 1: Arm B1: Forimtamig 0.3 mg + Carfilzomib | Cohort 1: Arm B2: Forimtamig 0.75 mg + Carfilzomib | Cohort 1: Arm B3: Forimtamig 1.5 mg + Carfilzomib |
|---|---|---|---|
| PyrexiaGeneral disorders | 3/7 | 5/6 | 3/6 |
| AnaemiaBlood and lymphatic system disorders | 1/7 | 4/6 | 4/6 |
| Aspartate aminotransferase increasedInvestigations | 0/7 | 4/6 | 0/6 |
| DysgeusiaNervous system disorders | 3/7 | 4/6 | 3/6 |
| Dry mouthGastrointestinal disorders | 4/7 | 0/6 | 3/6 |
| FatigueGeneral disorders | 4/7 | 1/6 | 2/6 |
| Cytokine release syndromeImmune system disorders | 4/7 | 3/6 | 3/6 |
| Alanine aminotransferase increasedInvestigations | 0/7 | 3/6 | 1/6 |
| Platelet count decreasedInvestigations | 1/7 | 3/6 | 1/6 |
| Decreased appetiteMetabolism and nutrition disorders | 2/7 | 2/6 | 3/6 |
Data for all participants randomized in the study have been presented.
| Age, Categorical(Participants) | Cohort 1: Arm B1: Forimtamig 0.3 mg + Carfilzomib | Cohort 1: Arm B2: Forimtamig 0.75 mg + Carfilzomib | Cohort 1: Arm B3: Forimtamig 1.5 mg + Carfilzomib | Total |
|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 2 | 4 | 6 | 12 |
| >=65 years | 5 | 3 | 1 | 9 |
| Sex: Female, Male(Participants) | Cohort 1: Arm B1: Forimtamig 0.3 mg + Carfilzomib | Cohort 1: Arm B2: Forimtamig 0.75 mg + Carfilzomib | Cohort 1: Arm B3: Forimtamig 1.5 mg + Carfilzomib | Total |
|---|---|---|---|---|
| Female | 4 | 2 | 2 | 8 |
| Male | 3 | 5 | 5 | 13 |
| Ethnicity (NIH/OMB)(Participants) | Cohort 1: Arm B1: Forimtamig 0.3 mg + Carfilzomib | Cohort 1: Arm B2: Forimtamig 0.75 mg + Carfilzomib | Cohort 1: Arm B3: Forimtamig 1.5 mg + Carfilzomib | Total |
|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 | 0 |
| Not Hispanic or Latino | 6 | 6 | 4 | 16 |
| Unknown or Not Reported | 1 | 1 | 3 | 5 |
| Race (NIH/OMB)(Participants) | Cohort 1: Arm B1: Forimtamig 0.3 mg + Carfilzomib | Cohort 1: Arm B2: Forimtamig 0.75 mg + Carfilzomib | Cohort 1: Arm B3: Forimtamig 1.5 mg + Carfilzomib | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 2 | 2 | 1 | 5 |
| Native Hawaiian or Other Pacific Islander | 1 | 0 | 0 | 1 |
| Black or African American | 0 | 0 | 0 | 0 |
| White | 3 | 5 | 4 | 12 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 1 | 0 | 2 | 3 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data_sharing
Ran from Dec 2023 to primary completion in Jul 2025, 19 months.
Results were first posted in Sep 2026, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
The study was terminated prematurely because the Sponsor decided not to pursue the development of forimtamig.
The study was terminated prematurely because the Sponsor decided not to pursue the development of forimtamig.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is terminated, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.